Log In
Print
BCIQ
Print
Print this Print this
 

Voraxaze, glucarpidase

  Manage Alerts
Collapse Summary General Information
Company BTG plc
DescriptionRecombinant enzyme that breaks down methotrexate in blood
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationPoisoning
Indication DetailsAdjunct for methotrexate (MTX) toxicity; Adjunctive treatment for the reduction of toxic methotrexate levels due to impaired renal function
Regulatory Designation

U.S. - Orphan Drug (Adjunctive treatment for the reduction of toxic methotrexate levels due to impaired renal function);
U.S. - Priority Review (Adjunctive treatment for the reduction of toxic methotrexate levels due to impaired renal function);
EU - Orphan Drug (Adjunctive treatment for the reduction of toxic methotrexate levels due to impaired renal function)

Partner

Ohara Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today